1. With any autoimmune disease, 2. with malignant tumors, 3. Participated in other clinical studies within three months before entering the group, 4. Severe allergic history, allergic to T cell therapy products or other biological agents, 5. Pregnant, planning to become pregnant or lactating women, 6. Patients with severe systemic diseases who are not suitable for entering the study, including but not limited to severe liver dysfunction, severe coagulation disorders, severe mental diseases, etc., 7. Previously received other stem cell therapy, had received CIK cell therapy within two months, 8. Researchers believe that other conditions should not be included in this trial.

1. With any autoimmune disease, 2. with malignant tumors, 3. Participated in other clinical studies within three months before entering the group, 4. Severe allergic history, allergic to T cell therapy products or other biological agents, 5. Pregnant, planning to become pregnant or lactating women, 6. Patients with severe systemic diseases who are not suitable for entering the study, including but not limited to severe liver dysfunction, severe coagulation disorders, severe mental diseases, etc., 7. Previously received other stem cell therapy, had received CIK cell therapy within two months, 8. Researchers believe that other conditions should not be included in this trial.